Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,155Revenue (TTM) $M24,754Net Margin (%)23.1Altman Z-Score2.0
Enterprise Value $M134,998EPS (TTM) $3.5Operating Margin %35.0Piotroski F-Score7
P/E(ttm)18.6Beneish M-Score-2.4Pre-tax Margin (%)30.1Higher ROA y-yY
Price/Book18.710-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %--Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow13.9y-y EBITDA Growth Rate %129ROA % (ttm)10.1Higher Current Ratio y-yY
Dividend Yield %3.4PEG--ROE % (ttm)116Less Shares Outstanding y-yY
Payout Ratio %62.0Shares Outstanding M1,629ROIC % (ttm)22.7Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVNWQ Managers 2016-06-30 Reduce-0.2%$57.12 - $65.09
($60.87)
$ 64.576%Reduce -28.08%562,288
ABBVJoel Greenblatt 2016-06-30 Add0.19%$57.12 - $65.09
($60.87)
$ 64.576%Add 40.22%905,598
ABBVDavid Dreman 2016-06-30 Reduce-0.1%$57.12 - $65.09
($60.87)
$ 64.576%Reduce -47.95%15,897
ABBVKen Fisher 2016-06-30 Reduce-0.01%$57.12 - $65.09
($60.87)
$ 64.576%Reduce -6.71%693,394
ABBVMario Gabelli 2016-06-30 Reduce$57.12 - $65.09
($60.87)
$ 64.576%Reduce -0.46%35,296
ABBVJoel Greenblatt 2016-03-31 Add0.28%$51.18 - $59.24
($55.77)
$ 64.5716%Add 216.32%645,835
ABBVJohn Paulson 2016-03-31 Sold Out -0.05%$51.18 - $59.24
($55.77)
$ 64.5716%Sold Out0
ABBVDavid Dreman 2016-03-31 Add0.03%$51.18 - $59.24
($55.77)
$ 64.5716%Add 16.28%30,542
ABBVNWQ Managers 2016-03-31 Add0.02%$51.18 - $59.24
($55.77)
$ 64.5716%Add 3.64%781,850
ABBVKen Fisher 2016-03-31 Reduce-0.02%$51.18 - $59.24
($55.77)
$ 64.5716%Reduce -20.51%743,284
ABBVMario Gabelli 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 64.5716%Reduce -12.66%35,460
ABBVDodge & Cox 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 64.5716%Reduce -0.07%33,232
ABBVNWQ Managers 2015-12-31 Reduce-0.65%$48.27 - $64.13
($57.69)
$ 64.5712%Reduce -50.59%754,413
ABBVFirst Eagle Investment 2015-12-31 Sold Out -0.14%$48.27 - $64.13
($57.69)
$ 64.5712%Sold Out0
ABBVJoel Greenblatt 2015-12-31 Add0.08%$48.27 - $64.13
($57.69)
$ 64.5712%Add 179.54%204,171
ABBVJohn Paulson 2015-12-31 Buy 0.05%$48.27 - $64.13
($57.69)
$ 64.5712%New holding139,700
ABBVDavid Dreman 2015-12-31 Reduce-0.03%$48.27 - $64.13
($57.69)
$ 64.5712%Reduce -15.80%26,267
ABBVKen Fisher 2015-12-31 Add$48.27 - $64.13
($57.64)
$ 64.5712%Add 0.77%935,104
ABBVMario Gabelli 2015-12-31 Reduce$48.27 - $64.13
($57.69)
$ 64.5712%Reduce -7.58%40,600
ABBVFirst Eagle Investment 2015-09-30 Add0.05%$52.5 - $71.23
($65.09)
$ 64.57-1%Add 55.71%1,056,150
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schumacher Laura JExecutive Vice President 2016-09-07Sell50,000$65-1.22view
Schumacher Laura JExecutive Vice President 2016-06-24Sell186,106$60.036.96view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-06-02Sell285,953$63.820.61view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-05-11Sell39,000$63.80.64view
HURWICH THOMAS A.VP, Controller 2016-05-10Sell6,000$63.590.97view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-05-10Sell21,583$63.521.09view
ALBAN CARLOSEVP, Commercial Operations 2016-05-10Sell47,438$63.521.09view
Schumacher Laura JExecutive Vice President 2016-03-08Sell25,000$56.0914.48view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-03-01Sell12,866$55.0516.64view
SALEKI-GERHARDT AZITASVP, Operations 2016-02-29Sell1,776$55.3815.94view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
AbbVie Joins BioArctic in Fight Against Parkinson’s Disease Sep 20 2016 
Is Marijuana Becoming Big Business? Sep 17 2016 
Gilead Sciences: Cheap Growth or Value Trap? Sep 13 2016 
AbbVie: Investors Apprehensive About Humira Sep 06 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 12 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 04 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Can Novartis Win the Entresto Bet? Aug 03 2016 
9 Best Stocks for Value Investors This Week Jul 26 2016 
An Unfair Valuation Makes a Great Investment Jul 15 2016 

More From Other Websites
Major Pharma Continues to See Rising Tide in Short Interest Sep 27 2016
Wall Street Sells Off on Worries Over Clinton-Trump Showdown Sep 26 2016
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies Sep 26 2016
As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble? Sep 26 2016
What’s the Upside Potential for Gilead? Sep 26 2016
AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy... Sep 26 2016
AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : September 26, 2016 Sep 26 2016
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb Sep 26 2016
Jefferies Makes Huge New Stock Addition to Franchise Picks List Sep 26 2016
7:05 am AbbVie submits a sNDA for ibrutinib to treat patients with marginal zone lymphoma Sep 26 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for... Sep 26 2016
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval Sep 26 2016
FDA Approves Amgen's Biosimilar Version of Humira Sep 23 2016
FDA approves lower-cost alternative to biotech drug Humira Sep 23 2016
FDA approves lower-cost alternative to biotech drug Humira Sep 23 2016
U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Sep 23 2016
U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira Sep 23 2016
Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX®... Sep 23 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir... Sep 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)